MADRID, July 16, 2014 /PRNewswire/ --
Biospain 2014 is currently seeking and selecting projects for presentation as part of its Investment Forum, one of the most high profile in the sector, for which 25 investment funds - 70% of which are international- have already confirmed their attendance, a figure the organisers expect to double.
This year the Forum will be bolstered by the presence of a wider range of investor profiles, a bigger international presence and more participating companies.
There are currently 10 available slots for companies and other entities wishing to pitch a business plan to the attending investors. In total, there will be 40 presentations over the three day duration of Biospain, each lasting 8-10 minutes, with alternating conferences on a wide range of investment issues (including corporate funds for big pharma, large international funds, PPP initiatives, business angels, industrial capital from non-pharma sectors and crowdfunding, to name a few).
Among the most important funds to attend Biospain feature companies such as Aravis Ventures (Switzerland), Caixa Capital Risc (Spain), Cross Road Biotech (Spain), Edmond de Rothschild Investment Partners (France), Forbion Capital Partners (Netherlands), Index Ventures (Switzerland), Johnson & Johnson Development Corporation (UK), LG Life Sciences (South Korea), Merck Serono Ventures (Germany), Novartis Venture Fund (Switzerland), Sofinnova Partners (France), Takeda Ventures (US), Ysios Capital Partners (Spain), Glaxo SmithKline Pharm
|SOURCE ASEBIO (Spanish Bioindustry Association)|
Copyright©2014 PR Newswire.
All rights reserved